



Proteomics, Unplugged

Powerful NGS-based proteomics effortlessly uncover meaningful insights

Unlimited insights, Untapped potential

Genomics + Proteomics: The Ultimate Partnership for Discovery

RNA

Proteomics takes the success of genomics further, offering dynamic, real-time insights into human biology and its changes—key for advancing precision medicine. Proteins bridge the gap between genotype and phenotype, while responding to the environment.

Unlocking the Power of Proteomics at Scale

Olink has been chosen to analyze 600,000 samples in the UK Biobank (UKB) Pharma Proteomics Project, the world's largest human proteogenomics study.

"To date, the scientific community has invested substantially in genomics for the advancement of precision medicine. However, to identify the right drug for the right patient at the right time, we must move beyond genomics alone. This dataset will help paint a much more nuanced and detailed picture of how the human genome and proteins circulating in the blood influence human health and disease – enabling biomedical researchers to identify new biological associations, find new drug targets and build blood-based diagnostics."

Dr Chris Whelan, Director, Neuroscience, Data Science & Digital Health, Janssen Research & Development, LLC, a Johnson & Johnson Company, Pharma Proteomics Project Lead.²

1 - https://www.nature.com/articles/s41586-023-06592-6 2 - https://www.ukbiobank.ac.uk/learn-more-about-uk-biobank/news

UKB Pilot Outcomes¹

Identified pathways for drug targets

Improved disease prediction scores

>14,000 protein QTLs identified

100s peer reviewed studies

44 As a genomics lab, it's important to leverage NGS-based proteomics, using a method that can work across a wide range of sample matrices with tools we already have in the lab.

Professor Chris Mason, Weill Cornell Medicine, NY

Welcome to Proteomics, Unplugged

Olink Reveal: Accessible NGS-based Proteomics

High-plex protein analysis, made accessible, flexible, and cost-effective.



for sequencing, getting useful results from the first sample cohorts.

Dr. Magnus Palmblad, Group Leader, Center for Proteomics & Metabolomics, Leiden University Medical Center

Powerful Content, Actionable Insights



Curated Content That Unlocks New Discoveries

Olink Reveal provides broad proteome coverage and deep profiling of inflammation and immune response.

Broad proteome coverage 100% top level pathways and 64% of all pathways

in Reactome¹

Deep profiling of inflammation 537 inflammation proteins covering 96% of immune response pathways in Reactome²

2 - Reactome, Open Targets and Gene Ontology

Curated library ~1,000 proteins, robustly detectable markers, with high proportion of cis-pQTLs for proteogenomics associations³

3 - PMID: 37794186, 39316441, 37794188



from 0-12. This remains close to Olink Explore HT coverage, which targets 5 times more proteins. 100% 80%



⁴⁴The number of proteins and breadth of pathways covered enabled us to identify proteins that may differentiate how leukemia patients respond differently to various BTK inhibitors over time. Due to its affordable cost, it would enable groups to scale testing across a large number of subjects and timepoints."

Professor Edvard Smith, Karolinska Institute



Volcano plots represent typical results obtained with Olink Reveal with pink markers denoting significant (adjusted p<0.05) and grey markers denoting non-significant

4Olink Reveal enabled us to identify biomarkers relevant for prediabetes that correlate with clinical data in our biobank samples.³³

Professor Karol Kaminski, Medical University Bialystok

Accessible Solution, Affordable Results





⁴⁴Core facilities will be interested in adopting Olink Reveal because there is no need for capex, and it just plugs into the normal genomics workflow.³³

Catharine Aquino, Functional Genomics Center Zurich, ETH Zürich

Trusted Technology, Demonstrated Results

PEA Technology: Trusted for Precision and Reliability

Olink Reveal leverages the power of Olink's Proximity Extension Assay (PEA) technology, demonstrated through more than 2,300 publications.



Setting the Standard for Proteomics Validation

Every assay is lab validated by our comprehensive 3-step, 15-factor assay validation process. The Olink Reveal library is enriched for proteins that are genetically validated.



V Olink

Olink Reveal Performance Specifications

- High Sensitivity: Detects as low as fg/ml
- Broad Compatibility: Validated in plasma and serum; compatible with various other matrices
- High Precision: Intra-plate CVs: 8.1% Inter-plate CVs: 4.8% Inter-site CVs: 6.3%
- Robust Marker Detection: Reliable performance across a wide range of biological markers
- Biological Detectability Range: 86-100%
- NGS Platform Compatibility: Supports multiple platforms, including NovaSeq X, NovaSeq 6000, NextSeq 2000, and more
- Reproducibility: High concordance with other Olink products based on overlapping content (R=0.95 Olink Explore HT, R=0.94 Olink Explore 3072, R=0.90 Olink Target 96 Inflammation) and high concordance between sites (R= 0.96-0.98)

Contact us to start your proteomics journey today with Olink Reveal or any of our other proteomics solutions at www.olink.com/reveal



Olink products and services are For Research Use Only. Not for use in diagnostic procedures. All information in this document is subject to change without notice. This document is not intended to convey any warranties, representations and/or recommendations of any kind, unless such warranties, representations and/or recommendations are explicitly stated. Olink assumes no liability arising from a prospective reader's actions based on this document. OLINK, NPX, PEA, PROXIMITY EXTENSION, INSIGHT and the Olink logotype are trademarks registered, or pending registration, by Olink Proteomics AB. All third-party trademarks are the property of their respective owners. Olink products and assay methods are covered by several patents and patent applications https://www.olink.com/patents/.

1586, v1.2, 2025-02-06

^{© 2025} Olink Proteomics AB, part of Thermo Fisher Scientific.